Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c (Q39368551)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c |
scientific article |
Statements
1 reference
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised c (English)
1 reference
Juan P Frías
1 reference
Cristian Guja
1 reference
Elise Hardy
1 reference
Azazuddin Ahmed
1 reference
Fang Dong
1 reference
Peter Öhman
1 reference
Serge A Jabbour
1 reference
15 September 2016
1 reference
1 reference
1004-1016
1 reference
Identifiers
1 reference